2023 Volume 163 Pages 59-65
Surgical resection is the standard treatment for tongue cancer. We conducted a retrospective investigation of the clinical outcomes of 202 patients with tongue cancer who were treated surgically at our institution.
The 5-year overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) rates in the overall subject population (n = 202) were 72%, 54%, and 78%, respectively.
The 5-year OS rates were 90%, 75%, 61%, and 46% in patients with T1, T2, T3, and T4 tumors, respectively. The 5-year DFS rates were 72%, 47%, 52%, and 41% in patients with T1, T2, T3, and T4 tumors, respectively. The 5-year DSS rates were 93%, 84%, 68%, and 49% in patients with T1, T2, T3, and T4 tumors, respectively.
The 5-year OS rates were 90%, 72%, 71%, and 53% in the patients classified as having Stage I, Stage II, Stage III, and Stage IV disease, respectively. The 5-year DFS rates were 71%, 45%, 63%, and 45% in the patients classified as having Stage I, Stage II, Stage III, and Stage IV disease, respectively. The 5-year DSS rates were 93%, 82%, 71%, and 61% in the patients classified as having Stage I, Stage II, Stage III, and Stage IV disease, respectively.
In patients with locally advanced disease (high T stage), the treatment outcomes were unsatisfactory. Therefore, further prospective analyses are recommended to improve the prognosis in patients with tongue cancer treated by surgery.
